AQST - Company ID 0001398733
The table below shows Aquestive Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $14.45M | $12.81M | $10.00M | $8.72M | $13.54M | $20.10M |
| Cost of revenue | $3.47M | $4.51M | $4.56M | $3.65M | $4.44M | $4.53M |
| Gross profit | - | - | - | - | - | - |
| R&D | $4.20M | $4.53M | $4.11M | $5.36M | $5.27M | $4.16M |
Aquestive Therapeutics, Inc. reported annual revenue of $44.55M for fiscal year 2025. That is down 22.6% from $57.56M in fiscal 2024. Over the 9 fiscal years shown, annual revenue declined from $66.92M (FY 2017) to $44.55M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $10.98M |
| $15.25M |
| $12.71M |
| $19.07M |
| $12.13M |
| $11.36M |
| Operating income | -$4.20M | -$11.48M | -$11.37M | -$19.36M | -$8.29M | $55.00K |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$8.06M | -$15.45M | -$13.55M | -$22.93M | -$11.51M | -$2.75M |
| EPS (diluted) | -$0.07 | -$0.14 | -$0.14 | -$0.24 | -$0.13 | -$0.03 |